Bone sarcoma
diseaseOn this page
Also known as osseous sarcomasarcoma of bonesarcoma of the boneskeletal sarcoma
Summary
Bone sarcoma (MONDO:0021054) is a cancer (an umbrella term covering 13 Mondo subtypes) and 52 clinical trials. Top therapeutic interventions include dalteparin sodium, dinutuximab beta, and enoxaparin sodium. A subtype of bone cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
- Umbrella term: 13 Mondo subtypes
- Clinical trials: 52
Clinical features
Epidemiology
Prevalence records
2 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.8 | Europe | Validated |
| Point prevalence | 1-9 / 100 000 | 9.29 | Europe | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | bone sarcoma |
| Mondo ID | MONDO:0021054 |
| Orphanet | 223727 |
| DOID | DOID:0080639 |
| NCIT | C9312 |
| SNOMED CT | 448710000 |
| UMLS | C1704327 |
| MedGen | 352831 |
| GARD | 0020547 |
| MedDRA | 10006007 |
| Anatomy (UBERON) | UBERON:0001474 |
| Is cancer (heuristic) | yes |
Also known as: bone sarcoma · osseous sarcoma · sarcoma of bone · sarcoma of the bone · skeletal sarcoma
Data availability: 10 cell lines.
Disease family
This is a subtype of bone cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › bone cancer › bone sarcoma
Related subtypes (11): bone chondrosarcoma, skull cancer, bone carcinoma, small cell osteogenic sarcoma, peripheral primitive neuroectodermal tumor of bone, sternum cancer, chest wall bone cancer, adult extraskeletal osteosarcoma, primary bone lymphoma, bone marrow cancer, cancer affecting bone of limb skeleton
Subtypes (13): undifferentiated pleomorphic sarcoma, bone angiosarcoma, undifferentiated high grade pleomorphic sarcoma of bone, bone fibrosarcoma, bone leiomyosarcoma, Ewing sarcoma of bone, bone osteosarcoma, liposarcoma of bone, periosteal chondrosarcoma, clear cell chondrosarcoma, dedifferentiated chondrosarcoma, bone giant cell tumor, malignancy in giant cell tumor of bone
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 52.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 22 |
| PHASE2 | 14 |
| PHASE1 | 6 |
| PHASE1/PHASE2 | 3 |
| EARLY_PHASE1 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE4 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03244020 | PHASE4 | ENROLLING_BY_INVITATION | LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology |
| NCT06669013 | PHASE3 | RECRUITING | Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas |
| NCT04963517 | PHASE2/PHASE3 | COMPLETED | Exercise Intervention for Bone Tumor Patients |
| NCT05057130 | PHASE2/PHASE3 | UNKNOWN | Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors |
| NCT03449108 | PHASE2 | ACTIVE_NOT_RECRUITING | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas |
| NCT03965234 | PHASE1/PHASE2 | RECRUITING | Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases |
| NCT04698785 | PHASE2 | RECRUITING | Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients |
| NCT06074692 | PHASE2 | RECRUITING | PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) |
| NCT06416085 | PHASE2 | ACTIVE_NOT_RECRUITING | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer |
| NCT06637007 | PHASE2 | RECRUITING | Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma |
| NCT07066982 | PHASE1/PHASE2 | RECRUITING | Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas |
| NCT07193550 | PHASE2 | RECRUITING | A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) |
| NCT01336803 | PHASE2 | COMPLETED | Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI |
| NCT01830153 | PHASE2 | COMPLETED | RAD001 in Advanced Sarcoma |
| NCT02301039 | PHASE2 | COMPLETED | SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas |
| NCT02500797 | PHASE2 | COMPLETED | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery |
| NCT02982486 | PHASE2 | UNKNOWN | A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma |
| NCT03277924 | PHASE1/PHASE2 | COMPLETED | Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas |
| NCT03468075 | PHASE2 | TERMINATED | Gemcitabine Plus Ascorbate for Sarcoma in Adults |
| NCT04906876 | PHASE2 | WITHDRAWN | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas |
| NCT05116800 | PHASE2 | WITHDRAWN | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma |
| NCT02811523 | PHASE1 | RECRUITING | In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma |
| NCT04616248 | PHASE1 | ACTIVE_NOT_RECRUITING | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors |
| NCT05621668 | PHASE1 | RECRUITING | A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma |
| NCT00423254 | PHASE1 | COMPLETED | Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. |
| NCT01803152 | PHASE1 | COMPLETED | Dendritic Cell Vaccine for Children and Adults With Sarcoma |
| NCT03462316 | PHASE1 | UNKNOWN | NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma |
| NCT04634227 | EARLY_PHASE1 | ACTIVE_NOT_RECRUITING | Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) |
| NCT02384473 | EARLY_PHASE1 | COMPLETED | Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma |
| NCT04877587 | EARLY_PHASE1 | WITHDRAWN | Gemcitabine With Ascorbate Including Adolescents |
| NCT03442465 | Not specified | RECRUITING | Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas |
| NCT04055220 | Not specified | RECRUITING | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas |
| NCT04122872 | Not specified | RECRUITING | GISAR German Interdisciplinary Sarcoma Registry |
| NCT04181970 | Not specified | RECRUITING | Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK |
| NCT05033288 | Not specified | RECRUITING | Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone |
| NCT05051059 | Not specified | RECRUITING | Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients |
| NCT05515068 | Not specified | NOT_YET_RECRUITING | Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas |
| NCT06129903 | Not specified | RECRUITING | Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma |
| NCT06409013 | Not specified | RECRUITING | Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma |
| NCT07215611 | Not specified | RECRUITING | Financial Toxicity in Patients With Resected Soft Tissue and Bone Sarcomas |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DALTEPARIN SODIUM | 4 | 1 |
| DINUTUXIMAB BETA | 4 | 1 |
| ENOXAPARIN SODIUM | 4 | 1 |
| FERUMOXYTOL | 4 | 1 |
| LIFILEUCEL | 4 | 1 |
| PERFLUTREN | 4 | 1 |
| PSILOCYBIN | 3 | 1 |
| ZANZALINTINIB | 3 | 1 |
| ELRAGLUSIB | 2 | 2 |
| HILTONOL | 2 | 1 |
| MEBUFOTENIN | 2 | 1 |
| ENOXAPARIN | 0 | 1 |